Press release

MORRISVILLE, N.C., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (Nasdaq: LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced that it will present two posters at the European Respiratory Society (ERS) 2026 Congress taking place September 5-9, 2026, in Barcelona, Spain.

Dr. Rajeev Saggar, M.D., Chief Medical Officer of Liquidia, said: “These presentations represent important steps in building the evidence around our inhaled treprostinil programs, which have the potential to meaningfully change the treatment experience for people living with pulmonary hypertension with interstitial lung disease.”

Poster Presentations

Patterns in interstitial lung disease: A snapshot of the baseline lung morphology in ILD-PH in the ASCENT study [NCT06129240]
Poster Session: PS-35
Date: September 7, 2026
Time: 8:00-9:30 CEST
Presenter: N. Kolaitis (University of California, San Francisco, United States)

Re-Spire: A Phase 3, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Pulmonary Hypertension With Interstitial Lung Disease, PH-ILD
Poster Session: PS-37
Date: September 8, 2026
Time: 12:30-14:00 CEST
Presenter: Prof. V. Cottin (Claude Bernard University Lyon 1, France)

About YUTREPIA^® (treprostinil) Inhalation Powder
YUTREPIA is an inhaled dry-powder formulation of treprostinil delivered through a convenient, low-effort, palm-sized device. YUTREPIA is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) to improve exercise ability. YUTREPIA was designed using Liquidia’s PRINT^® technology, which enables the development of drug particles that are precise and uniform in size, shape and composition, and that are engineered for enhanced deposition in the lung following oral inhalation. YUTREPIA was previously referred to as LIQ861 in investigational studies.

About L606 (liposomal treprostinil inhalation suspension)
L606 is an investigational, extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer. The L606 suspension uses a proprietary liposomal formulation to encapsulate treprostinil which can be released slowly at a controlled rate into the lung, enhancing drug exposure over an extended period of time. L606 is currently being evaluated in an open-label study in the United States for treatment of PAH and PH-ILD and is the subject of Re-Spire, a global pivotal placebo-controlled efficacy study for the treatment of PH-ILD.

About Liquidia Corporation
Liquidia Corporation is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases through precise, innovative therapies and applications of its proprietary PRINT^® technology. PRINT enabled the development of YUTREPIA^® (treprostinil) inhalation powder for the treatment of PAH and PH-ILD. The company is also developing L606, an investigational extended-release formulation of treprostinil administered twice daily with a next-generation nebulizer, and currently markets generic Treprostinil Injection for the treatment of PAH. To learn more about Liquidia, please visit www.liquidia.com.

Contacts:

Investors
Jason Adair
Chief Business Officer
919.328.4350
jason.adair@liquidia.com

Media
media@liquidia.com